San Jose, California-based medical device company SI-BONE Inc has appointed Karen Licitra and Keith Valentine to its board of directors. Recently, Licitra worked at Johnson & Johnson where she was a corporate vice president while Valentine is president and CEO of SeaSpine Holdings Corp. SI-BONE’s backers include Redline Capital Management, Orbimed, Novo A/S, Skyline Ventures and Montreux Equity Partners.Continue
Irvine, California-based Kareo, a cloud-based solutions provider for independent medical practices, has raised $55.4 million in funding. Montreux Equity Partners led the round with participation from other investors that included Silver Lake Waterman and all of Kareo’s existing investors.Continue
Rock Health, a San Francisco-based digital health accelerator, has received an undisclosed amount of seed funding, the company announced in a blog post on its site. Bessemer Venture Partners and Kaiser Permanente Ventures led the round with participation from KPCB, Montreux Equity Partners and Great Oaks Ventures. To read more details about the funding, visit here.Continue
If you want proof secondary purchases can lift portfolio performance, look no further than the [...]Continue
Epirus Biopharmaceuticals said Wednesday that it has secured $36 million in Series B funding. Livzon Mabpharm led the round with participation from other investors that include Adage Capital, Greenwoods Investment, Gibralt US, Monashee Capital Partners, TPG Biotech, Montreux Equity Partners and 5AM Ventures. Also, Epirus will merge with Zalicus. No financial terms were disclosed. The merged entity will be led by Amit Munshi as president and CEO. Based in Boston, Epirus is a biopharmaceutical firm focused on biosimilar monoclonal antibodies while Zalicus specializes in developing new treatments for patients suffering from pain and inflammation.Continue
Colorescience has closed a $10 million Series A convertible preferred stock offering from existing investors. The company also announced additions of two members to its board of directors, Josh Baltzell of Split Rock Partners and Howard Palefsky of Montreux Equity Partners.Continue
Tobira Therapeutics, a developer of innovative antiretroviral therapies for HIV, has appointed three executives in the finance, clinical and pharmaceutical sciences functions. Caroline Loewy joins the company as executive vice president and chief financial officer, Jeff Enejosa, M.D., as senior director, clinical research, and Mark Menning as director, pharmaceutical sciences. Tobira has financial backing from […]Continue
Hollywood, Florida-based Renal CarePartners has been acquired by Ambulatory Services of America, nd its subsidiary, Innovative Dialysis Systems. Renal CarePartners currently owns interests in and manages 17 dialysis centers in eight states and the territory of Puerto Rico, providing care to approximately 1,100 patients. The company’s private equity sponsors are Montreux Equity Partners and Noro-Moseley […]Continue
Sunnyvale, Calif.-based Pivot Medical, which develops minimally invasive hip restoration technologies, has raised $32 million in Series C financing. Adams Street Partners, a new investor, led the round. New investor Delphi Ventures, founding investor Montreux Equity Partners, and existing investor Ivy Capital Partners also contributed.Continue
SI-BONE, the Calif.-based medical device company that treats the sacroiliac joint, received a $16 million round of funding that was led by Montreux Equity Partners in Menlo Park. Skyline Ventures also participated in the round. John Savarese, M.D., Managing Director at Montreux, will join the SI-BONE Board of Directors.Continue
Tobira Therapeutics Inc. hired Andrew Hindman as president and chief executive officer. Hindman was Nodality Inc.’s senior vice president of corporate development.Tobira is a N.J.-based biopharmaceutical company that is focused on developing therapies for HIV infection. It is backed by Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.Continue
peHUB readers tell me they’d like to learn more about potential funding opportunities that might not yet be in their deal pipeline. With that in mind, we’ve put together a list of companies that are still in the market, based on SEC filings and our own reporting.
Know about other companies that should be on this list? Let me know at [email protected] And if you’re on this list and have raised money since your last SEC filing, please shoot me an email so I can update readers.
Below this list, you’ll find another section about companies that have concluded their fundraising efforts…Continue
Pulmonx, an emerging leader in interventional pulmonology, announced today that it has concluded an agreement for a new round of equity financing from an investment syndicate led by two new investors. The company also announced that it plans to use this capital to support the international commercial launch of its Zephyr® Endobronchial Valve (EBV), and its recently approved Chartis® Pulmonary Assessment System. Both products are CE marked and cleared for sale in Europe and other major international markets. The company expects that this round of financing will fund the expansion of its commercial operations through to positive cash flow and profitability.Continue